The News: M&A Beyond Wall Street

Biopharmaceutical company Biogen has hired Michael E. Lytton, formerly a general partner at the venture firm Oxford Bioscience Partners, to be its executive vice president of business and corporate development. As the Deal points out, the move comes as Biogen is exploring the purchase of Acorda Therapeutics to get to a multiple sclerosis treatment it has under development. Since a lot of growth in the pharmaceutical world happens through acquisition, it's easy to see where companies in the sector would value talent like Lytton's, and why exploring opportunities there could be a smart move for people looking for a new area to put their financial skills to work.

Biogen hires for M&A, may buy Acorda Therapeutics [The Deal]

Geithner has so many banks to save, so little help [ABC News]

Lehman's selling its VC unit to management [Reuters]

Now we'll find out who really wants to be an investment banker [Reuters via HedgeWorld]

Smith Barney's fighting to keep its clients [InvestmentNews]

People

Three senior Lehman bankers join Macquarie [The Deal]

David Sult becomes Aon Consulting's SVP for Corporate Transactions [Aon via PRN]

It's official: Ketchum is FINRA's Chief Executive [Finra via BW]

Joseph A. Moran joins Brenner Group as VP in its clean tech practice [Brenner via BW]

Northern Trust appoints James D. McDonald as chief investment strategist [NT via PRN]

George Froley joins GAMCO as convertible strategies consultant [GAMCO via BW]